Business

Cardax Launches Digital Corporate Communication Channels

Check out our press release hub, powered by Business Wire. It's a one stop shop for industry announcements to help you stay on top of the latest technology and investment trends. Get the scoop here.

Publishes Initial Blog Post on The Chairman’s Blog

HONOLULU–(BUSINESS WIRE)–April 22, 2014–

Cardax, Inc. (“Cardax” or the “Company”) (OTCQB: CDXI), announced today a suite of online corporate communication channels to maintain on-going direct communication with shareholders and other interested parties. The Company has launched official portals on social media channels including Facebook, Twitter, LinkedIn, Google+, YouTube, and The Chairman’s Blog.

The Chairman’s Blog is an online communication portal where Cardax executives can address important topics as they relate to the Company’s industry and technology as well as specific points of discussion as they relate to key events at Cardax. President and CEO, David G. Watumull, penned his inaugural blog post, “Astaxanthin for Human Use, The Origin of Cardax.” The blog post can be found online at the Cardax Chairman’s Blog profile provided below.

“While we will continue to issue press releases in connection with all major corporate developments, we are pleased to announce the launch of our social media channels, which will provide a forum for additional commentary and enable us to maintain a regular dialogue with interested parties,” said David G. Watumull, President and CEO.

Links to the new communication tools are here:

Facebook: https://www.facebook.com/cardaxpharma

Twitter: https://twitter.com/cardaxpharma

LinkedIn: https://www.linkedin.com/company/cardax-pharmaceuticals-inc-

Google+: https://plus.google.com/u/1/114677726793696614449/posts

YouTube: https://www.youtube.com/user/cardaxpharma

The Chairman’s Blog Profile: http://www.thechairmansblog.com/cardax

About Cardax

Cardax is a development stage life sciences company that devotes substantially all of its efforts to developing nutraceutical and pharmaceutical products that provide the anti-inflammatory benefits of steroids or NSAIDS, but with exceptional safety profiles, as conferred by U.S. Food and Drug Administration (“FDA”) Generally Recognized as Safe (“GRAS”) designation at certain doses. Cardax is preparing proprietary nature-identical products and related derivatives by total synthesis to provide scalable, pure, and economical therapies for diseases where inflammation and oxidative stress are strongly implicated, including, but not limited to, osteoarthritis, rheumatoid arthritis, dyslipidemia, metabolic disease, diabetes, cardiovascular disease, hepatitis, cognitive decline, macular degeneration, and prostate disease. The initial primary focus of Cardax is its astaxanthin technologies. Astaxanthin is a powerful and safe naturally occurring anti-inflammatory and anti-oxidant without the adverse side effects typical of anti-inflammatory treatments using steroids or NSAIDS, including immune system suppression, liver damage, cardiovascular disease risk, and gastrointestinal bleeding.

About TheChairmansBlog.com

TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog.com

Safe Harbor

This release may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions.

Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of our company, are generally identified by use of words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “seek,” “strive,” “try,” or future or conditional verbs such as “could,” “may,” “should,” “will,” “would,” or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Some of the factors that could cause our actual results to differ from our expectations or beliefs include, without limitation, the risks discussed from time to time in our filings with the Securities and Exchange Commission.

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, we undertake no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.

Cardax
Janice Kam, 808-457-1400
press@cardaxpharma.com


We're studying digital marketing compensation: how much companies pay CMOs, CDOs, VPs of marketing, and more, with ChiefDigitalOfficer. Help us out by filling out the survey, and we'll share the results with you.
0 comments